Navigation Links
Scientists' breakthrough attracts new funding for high blood pressure research
Date:6/21/2011

Scientists at the University of Strathclyde's Institute of Pharmacy and Biomedical Sciences, have recently been awarded almost 155,000 by the British Heart Foundation to conduct a two year investigation aimed at improving the treatment of hypertension.

Dr Debbi MacMillan and joint recipients of the award, Prof John McCarron and Dr Charles Kennedy, have identified a novel mechanism for the control of blood vessel constriction, essential in blood pressure regulation, which may lead to the development of new treatments for high blood pressure.

The researchers have identified a heretofore unrecognised pathway which regulates calcium activity within the smooth muscle of the blood vessel wall, to control constriction and dilation of blood vessels. The constriction and dilation of the muscular walls of blood vessels is controlled by calcium, which regulates blood flow through the vessels and thus blood pressure within the vessels. Yet, until now, a mechanism whereby calcium is regulated by the purinergic drug, ATP, has not been recognised.

This study will investigate the process by which ATP modifies calcium to regulate the constriction and dilation of blood vessels and how this may be altered in disease.

The new 36M building where Dr MacMillan is based is due to be officially opened later in 2011 as part of the world-class Institute at the University of Strathclyde for the discovery and development of new drugs to treat global diseases. An 8M fundraising campaign for the new drug development facility has attracted significant philanthropic support from Charities, Trusts and Strathclyde alumni resulting in 7M raised to date with additional donors still required. http://www.strath.ac.uk/alumni/healthclub/

The lead investigator, Dr MacMillan, said, "I am delighted that we have received funding from the British Heart Foundation. This prestigious award will enable us to gain a better understanding of the normal physiology of smooth muscle and how it might be changed in disease conditions, to provide better informed treatment, which leads to better management of the disease.

"Our findings will undoubtedly present new opportunities for the development of new drugs for treating vascular disorders."

Despite advances in medication targeting against hypertension, the underlying cause of the disease remains unclear and current medication is limited in achieving effective blood pressure control. A contributing factor is a poor understanding of the normal regulation of blood pressure and alterations which occur in the hypertensive patient. Key to understanding blood pressure control is an appreciation of smooth muscle, which is present within the walls of a number of organs in the body including blood vessels.

It is hoped that effective drug therapy to treat the underlying cause of the disease may avoid the need for long-term anti-hypertensive medicines.


'/>"/>

Contact: Corporate Comms
corporatecomms@strath.ac.uk
University of Strathclyde
Source:Eurekalert  

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. Scientists identify novel inhibitor of human microRNA
3. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
4. MU scientists go green with gold, distribute environmentally friendly nanoparticles
5. Scientists identify gene that may contribute to improved rice yield
6. Scientists discover why a mothers high-fat diet contributes to obesity in her children
7. MU scientists see how HIV matures into an infection
8. Earth scientists keep an eye on Texas
9. Thinking it through: Scientists call for policy to guide biofuels industry toward sustainability
10. Scientists identify a molecule that coordinates the movement of cells
11. Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists' breakthrough attracts new funding for high blood pressure research 
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology: